NCT07067853View on ClinicalTrials.gov

Effectivity and Safety of GB20 Acupoint Pharmacopuncture With Lidocaine 2% on Migraine Patients

NANot yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

December 1, 2025

Study Completion Date

January 1, 2026

Conditions
Migraine
Interventions
DEVICE

Lidocaine 2 % Pharmacopuncture

Injection of 0.5mL Lidocaine 2% solution into GB20 acupuncture point, both sides every week for 4 week

DRUG

propranolol 20mg

Propranolol 20mg, twice daily for 28 day / 4 week

Trial Locations (1)

10430

Universitas Indonesia, Jakarta Pusat

All Listed Sponsors
lead

Indonesia University

OTHER

NCT07067853 - Effectivity and Safety of GB20 Acupoint Pharmacopuncture With Lidocaine 2% on Migraine Patients | Biotech Hunter | Biotech Hunter